Abstract:β-catenin concentration is methodically controlled by the Wnt signaling pathway, wherein mutations of this pathway can cause aberrant activation leading to an influx of β-catenin, which is implicated in many cancers, specifically colon cancer. Targeting the β-catenin-TCF interface has become a popular strategy because of its role in the Wnt signaling transduction pathway, but efforts to push a small-molecule inhibitor to clinical success have been futile. In our current study, we attempted to identify druggable “hot spots” at the β-catenin-TCF interface by exploring plausible binding modes of a number of reported and chemically distinct inhibitors and defined their structure-based pharmacophore. Validation of our 4-feature pharmacophore hypothesis was carried out using another series of structure-related inhibitors with reported experimental data. Our hypothesis identified 73% of true actives with high enrichment of the most potent molecules in the test dataset. We speculate that our structure-based pharmacophore query may act as an in silico tool to rapidly screen small-molecule libraries for potentially new scaffolds to disrupt the β-catenin-TCF protein–protein interaction. In addition, our pharmacophore successfully identified actives from a set of structurally similar inhibitors and, ultimately, may be applied as an adjunct tool in the hit-to-lead optimization process.

Convenient Synthesis of Toxoflavin that Targets β‐Catenin/Tcf4 Signaling Activities

New Synthesis of Pyrvinium That Inhibits the Β-Catenin/tcf4 Pathway

New Synthetic Method of Ciprofloxacin

Design and Synthesis of TPP+-Mitomycin C Conjugate with Reduced Toxicity.

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

A Signal Transduction Cascade From Defense Signal Response To Taxoid Biosynthesis By Elicitation Of A Novel Synthetic Benzothiadiazole In Taxus Chinensis

[Improved method of fluvoxamine synthesis].

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Design, synthesis, and biological evaluation of new diaminoquinazolines as β-catenin/Tcf4 pathway inhibitors.

An Improved Synthesis and Cytotoxicity Activities of Catalpalactone

Toxoflavin analog D43 exerts antiproliferative effects on breast cancer by inducing ROS-mediated apoptosis and DNA damage

Synthesis, Conformational Analysis and Biological Evaluation of the Lactam Analogue of the Cyclodepsipeptide Apratoxin A

A New Strategy to Improve the Metabolic Stability of Lactone: Discovery of (20S,21s)-21-fluorocamptothecins As Novel, Hydrolytically Stable Topoisomerase I Inhibitors

Synthesis of N-(3-chloro-4-fluorophenyl)-6-nitro-7-((tetrahydrofuran-3-yl) oxy) quinazolin-4-amine

Synthesis of a FTO inhibitor with anticonvulsant activity.

Total Synthesis of 7-Ethyl-10-hydroxycamptothecin (SN38) and Its Application to the Development of C18-functionalized Camptothecin Derivatives.

Development of a Novel Fluorescence Polarization–Based Assay for Studying the Β-Catenin/tcf4 Interaction

Synthesis of Wogonin, a Natural Product with Anticancer Activity

Cu-catalyzed mild and efficient oxidation of THβCs using air: application in practical total syntheses of perlolyrine and flazin

Unprecedented Synthesis, in Vitro and in Vivo Anti-Cancer Evaluation of Novel Triazolonaphthalimide Derivatives.

Synthesis of Oleanolic Acid-Dithiocarbamate Conjugates and Evaluation of Their Broad-Spectrum Antitumor Activities